236 related articles for article (PubMed ID: 31748349)
1. Functional Attributes of Antibodies, Effector Cells, and Target Cells Affecting NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity.
Temming AR; de Taeye SW; de Graaf EL; de Neef LA; Dekkers G; Bruggeman CW; Koers J; Ligthart P; Nagelkerke SQ; Zimring JC; Kuijpers TW; Wuhrer M; Rispens T; Vidarsson G
J Immunol; 2019 Dec; 203(12):3126-3135. PubMed ID: 31748349
[TBL] [Abstract][Full Text] [Related]
2. Two mechanisms of the enhanced antibody-dependent cellular cytotoxicity (ADCC) efficacy of non-fucosylated therapeutic antibodies in human blood.
Iida S; Kuni-Kamochi R; Mori K; Misaka H; Inoue M; Okazaki A; Shitara K; Satoh M
BMC Cancer; 2009 Feb; 9():58. PubMed ID: 19226457
[TBL] [Abstract][Full Text] [Related]
3. Characterization of FcγRIIIA effector cells used in in vitro ADCC bioassay: Comparison of primary NK cells with engineered NK-92 and Jurkat T cells.
Hsieh YT; Aggarwal P; Cirelli D; Gu L; Surowy T; Mozier NM
J Immunol Methods; 2017 Feb; 441():56-66. PubMed ID: 27939300
[TBL] [Abstract][Full Text] [Related]
4. FcγR Binding and ADCC Activity of Human IgG Allotypes.
de Taeye SW; Bentlage AEH; Mebius MM; Meesters JI; Lissenberg-Thunnissen S; Falck D; Sénard T; Salehi N; Wuhrer M; Schuurman J; Labrijn AF; Rispens T; Vidarsson G
Front Immunol; 2020; 11():740. PubMed ID: 32435243
[TBL] [Abstract][Full Text] [Related]
5. Regulation of antibody-dependent cellular cytotoxicity by IgG intrinsic and apparent affinity for target antigen.
Tang Y; Lou J; Alpaugh RK; Robinson MK; Marks JD; Weiner LM
J Immunol; 2007 Sep; 179(5):2815-23. PubMed ID: 17709495
[TBL] [Abstract][Full Text] [Related]
6. Characterization of in vitro antibody-dependent cell-mediated cytotoxicity activity of therapeutic antibodies - impact of effector cells.
Chung S; Lin YL; Reed C; Ng C; Cheng ZJ; Malavasi F; Yang J; Quarmby V; Song A
J Immunol Methods; 2014 May; 407():63-75. PubMed ID: 24704820
[TBL] [Abstract][Full Text] [Related]
7. Fc-galactosylation modulates antibody-dependent cellular cytotoxicity of therapeutic antibodies.
Thomann M; Reckermann K; Reusch D; Prasser J; Tejada ML
Mol Immunol; 2016 May; 73():69-75. PubMed ID: 27058641
[TBL] [Abstract][Full Text] [Related]
8. Enhanced Effector Functions Due to Antibody Defucosylation Depend on the Effector Cell Fcγ Receptor Profile.
Bruggeman CW; Dekkers G; Bentlage AEH; Treffers LW; Nagelkerke SQ; Lissenberg-Thunnissen S; Koeleman CAM; Wuhrer M; van den Berg TK; Rispens T; Vidarsson G; Kuijpers TW
J Immunol; 2017 Jul; 199(1):204-211. PubMed ID: 28566370
[TBL] [Abstract][Full Text] [Related]
9. Compensation of endogenous IgG mediated inhibition of antibody-dependent cellular cytotoxicity by glyco-engineering of therapeutic antibodies.
Nechansky A; Schuster M; Jost W; Siegl P; Wiederkum S; Gorr G; Kircheis R
Mol Immunol; 2007 Mar; 44(7):1815-7. PubMed ID: 17011625
[TBL] [Abstract][Full Text] [Related]
10. Antibody-Dependent Cellular Cytotoxicity Activity of Effector Cells from HIV-Infected Elite and Viral Controllers.
Isitman G; Lisovsky I; Tremblay-McLean A; Kovacs C; Harris M; Routy JP; Bruneau J; Wainberg MA; Tremblay C; Bernard NF
AIDS Res Hum Retroviruses; 2016; 32(10-11):1079-1088. PubMed ID: 27499379
[TBL] [Abstract][Full Text] [Related]
11. Differential inhibition of trastuzumab- and cetuximab-induced cytotoxicity of cancer cells by immunoglobulin G1 expressing different GM allotypes.
Namboodiri AM; Pandey JP
Clin Exp Immunol; 2011 Dec; 166(3):361-5. PubMed ID: 22059994
[TBL] [Abstract][Full Text] [Related]
12. Human IgG2 antibodies against epidermal growth factor receptor effectively trigger antibody-dependent cellular cytotoxicity but, in contrast to IgG1, only by cells of myeloid lineage.
Schneider-Merck T; Lammerts van Bueren JJ; Berger S; Rossen K; van Berkel PH; Derer S; Beyer T; Lohse S; Bleeker WK; Peipp M; Parren PW; van de Winkel JG; Valerius T; Dechant M
J Immunol; 2010 Jan; 184(1):512-20. PubMed ID: 19949082
[TBL] [Abstract][Full Text] [Related]
13. FcγRIIIb Restricts Antibody-Dependent Destruction of Cancer Cells by Human Neutrophils.
Treffers LW; van Houdt M; Bruggeman CW; Heineke MH; Zhao XW; van der Heijden J; Nagelkerke SQ; Verkuijlen PJJH; Geissler J; Lissenberg-Thunnissen S; Valerius T; Peipp M; Franke K; van Bruggen R; Kuijpers TW; van Egmond M; Vidarsson G; Matlung HL; van den Berg TK
Front Immunol; 2018; 9():3124. PubMed ID: 30761158
[TBL] [Abstract][Full Text] [Related]
14. An improved method to quantify human NK cell-mediated antibody-dependent cell-mediated cytotoxicity (ADCC) per IgG FcR-positive NK cell without purification of NK cells.
Sung AP; Tang JJ; Guglielmo MJ; Redelman D; Smith-Gagen J; Bateman L; Hudig D
J Immunol Methods; 2018 Jan; 452():63-72. PubMed ID: 29113954
[TBL] [Abstract][Full Text] [Related]
15. Development of a robust reporter-based ADCC assay with frozen, thaw-and-use cells to measure Fc effector function of therapeutic antibodies.
Cheng ZJ; Garvin D; Paguio A; Moravec R; Engel L; Fan F; Surowy T
J Immunol Methods; 2014 Dec; 414():69-81. PubMed ID: 25086226
[TBL] [Abstract][Full Text] [Related]
16. Expression of a Recombinant High Affinity IgG Fc Receptor by Engineered NK Cells as a Docking Platform for Therapeutic mAbs to Target Cancer Cells.
Snyder KM; Hullsiek R; Mishra HK; Mendez DC; Li Y; Rogich A; Kaufman DS; Wu J; Walcheck B
Front Immunol; 2018; 9():2873. PubMed ID: 30574146
[TBL] [Abstract][Full Text] [Related]
17. Chronic HIV-1 Infection Alters the Cellular Distribution of FcγRIIIa and the Functional Consequence of the FcγRIIIa-F158V Variant.
Phaahla NG; Lassaunière R; Da Costa Dias B; Waja Z; Martinson NA; Tiemessen CT
Front Immunol; 2019; 10():735. PubMed ID: 31024562
[TBL] [Abstract][Full Text] [Related]
18. Combined Fc-protein- and Fc-glyco-engineering of scFv-Fc fusion proteins synergistically enhances CD16a binding but does not further enhance NK-cell mediated ADCC.
Repp R; Kellner C; Muskulus A; Staudinger M; Nodehi SM; Glorius P; Akramiene D; Dechant M; Fey GH; van Berkel PH; van de Winkel JG; Parren PW; Valerius T; Gramatzki M; Peipp M
J Immunol Methods; 2011 Oct; 373(1-2):67-78. PubMed ID: 21855548
[TBL] [Abstract][Full Text] [Related]
19. Canine non-B, non-T NK lymphocytes have a potential antibody-dependent cellular cytotoxicity function against antibody-coated tumor cells.
Kim Y; Lee SH; Kim CJ; Lee JJ; Yu D; Ahn S; Shin DJ; Kim SK
BMC Vet Res; 2019 Oct; 15(1):339. PubMed ID: 31610784
[TBL] [Abstract][Full Text] [Related]
20. Tumour antigen targeted monoclonal antibodies incorporating a novel multimerisation domain significantly enhance antibody dependent cellular cytotoxicity against colon cancer.
Jain A; Poonia B; So EC; Vyzasatya R; Burch EE; Olsen HS; Mérigeon EY; Block DS; Zhang X; Schulze DH; Hanna NN; Twadell WS; Yfantis HG; Chan SL; Cai L; Strome SE
Eur J Cancer; 2013 Oct; 49(15):3344-52. PubMed ID: 23871153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
